Business Wire

PACE-TELEMATICS

31.7.2024 14:01:33 CEST | Business Wire | Press release

Share
Europe’s Largest Gas Station Network: PACE Telematics Surpasses the 10,000 Mark

PACE Telematics, a leading provider of mobile payment solutions in the European gas station market, is proud to announce a significant milestone: The company now enables mobile payments at over 10,000 gas stations in 15 European countries. Renowned brands such as Esso, JET, OMV, and TAMOIL are among its gas station partners. By integrating with PACE's Connected Fueling platform, they are part of Europe's largest digital gas station network. This achievement positions PACE as Europe’s market leader and highlights the growing importance of mobile payment solutions in the gas station sector.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240731147479/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

PACE Telematics Surpasses the 10,000 Mark and Becomes Europe’s Largest Gas Station Network. (Graphic: Business Wire)

An increasing number of consumers are using their smartphones, wearables, or in-car applications for payments. This has been highlighted by the fifth edition of the Visa Payment Monitor 2023 in collaboration with the opinion research institute forsa. According to a representative online survey of 1,700 people in Germany, nearly one in four people (23 percent) pay with their mobile phone or wearables, such as smartwatches, compared to only six percent four years ago – indicating that mobile payments are gaining momentum. Reasons for this development include the growing implementation and acceptance of mobile payment technologies, as well as the convenience and efficiency they offer. According to an analysis by the Boston Consulting Group, the European leaders in mobile payments are Norway, Denmark, and Luxembourg.

PACE Becomes Europe's Largest Gas Station Network

The trend is also clearly noticeable in the gas station business: PACE's network, which enables mobile payments via app, wearable, or vehicle directly at the pump through the Connected Fueling platform, is the first provider to surpass the 10,000 mark. PACE has become the largest gas station network in Europe, spanning a total of 15 European countries. Renowned brands such as Esso, JET, OMV, TAMOIL and many more are among the partners. At these stations, mobile payments are now used by over 1.3 million users.

Connected Fueling Platform Offers Numerous Advantages

The Connected Fueling platform by PACE offers numerous advantages to gas station operators, fuel card issuers, app providers, and automotive manufacturers by enabling mobile payments at the pump. These advantages include increased convenience through digital receipts and mobile payments, faster payment processing, and improved service in the shop due to shorter waiting times and reduced workloads for employees.

The connection to the platform is technically uncomplicated for gas station partners. To ensure smooth communication, the respective POS system is connected to the PACE Connected Fueling platform. The PACE interface "Open Fueling Site Connect" (OpenFSC) is a free open-source API used by most connected industry partners, such as Ratio Elektronik, to quickly and easily connect to the Connected Fueling platform. PACE already has numerous existing integrations with various POS system providers such as Fortech, Scheidt & Bachmann or TSG Deutschland and many more.

Plug-and-Play Solution: Maximizing Business Success in Europe

The Connected Fueling platform offers an innovative plug-and-play solution that enables gas stations, fuel and fleet card providers, mobility apps, and car manufacturers to comprehensively digitize and establish presence in the European market. While previous integration projects and multi-million investments were necessary for plastic fuel cards to enter the European market, fuel card partners can now operate quickly and efficiently across Europe with just one integration into the platform. More and more fuel card issuers such as DKV, Esso, Hoyer, or LOGPAY are taking advantage of these benefits.

Furthermore, additional mobility use cases are on the roadmap based on the technical foundation of the platform, which will expand the offering in the near future, including, for example, mobile car wash payments.

About PACE Telematics & Connected Fueling

The open Connected Fueling platform, operated by PACE Telematics (Karlsruhe, Germany), enables seamless mobile payment directly at the fuel pump through a uniform, cost-saving integration of all partners with the Connected Fueling cloud system. The independent platform is open to all petroleum companies, service station operators, fuel card issuers and POS system providers. Additionally, the platform offers automobile manufacturers and app developers flexible interfaces and easily integrable Software Development Kits (SDKs) to incorporate the mobile payment functionality into their systems. For more information, please visit www.connectedfueling.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240731147479/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release

Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release

Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye